Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Revenue Estimates

Below are the top diagnostic substances stocks on the NASDAQ in terms of revenue estimate for the current year. Analysts expect IDEXX Laboratories

to post revenue of $1.30 billion for the year ending December, 2012. IDEXX had $221.44 million in total cash for the latest quarter. Neogen

is likely to post revenue of $205.21 million in the year ending May, 2013. Neogen's trailing-twelve-month operating margin is 19.11%. Meridian Bioscience

is expected to report revenue of $189.80 million for the year ending September, 2013. Meridian Bioscience's trailing-twelve-month ROE is 23.73%. Abaxis

may report revenue of $182.77 million in the year ending March, 2013. Abaxis' PEG ratio is 3.40.